Impact of postinduction PET-CT on PFS in 104 randomly assigned patients in the PRIMA study. (A) Observation arm (n = 57). PET negative designates patients (n = 43) with a negative PET-CT after induction therapy, and PET positive designates those (n = 14) with a positive PET-CT. Log-rank P = .010. (B) Rituximab maintenance arm (n = 47). PET negative designates patients (n = 38) with a negative PET-CT after induction therapy, and PET positive designates those (n = 9) with a positive PET-CT. Log-rank P = .17. N/A, not applicable; PET-CT, positron emission tomography–computed tomography; PFS, progression-free survival; PRIMA, Primary Rituximab and Maintenance. Reprinted from Trotman et al.¹ with permission.